This relates not only to a higher prevalence of risk factors for cardiovascular disease such as dyslipidaemia, abdominal adiposity, hypertension, and diabetes mellitus in the breast cancer population [7], but is increased exponentially by Cancer Treatment-Related Cardiac Dysfunction (CTRCD), particularly in patients with Her2-positive breast cancer exposed to multimodal cancer therapy. The gene discussed is ERBB2; the disease is cancer.